Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Pacific Biosciences Calif In (PACB)

226 + Investors. Track Smart Money conviction in PACB. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +12
Streak
3Q ▲
Buyers last Q
51%

Smart Money Signals — PACB

Based on 227 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added PACB than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
📊

High ownership — 87% of 3.0Y peak

87% of all-time peak
227 funds currently hold this stock — 87% of the 3.0-year high of 260 funds (reached 2023 Q3). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +5% more funds vs a year ago

fund count last 6Q
+10 new funds entered over the past year (+5% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 51% buying

113 buying110 selling
Last quarter: 113 funds bought or added vs 110 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~50 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 30 → 28 → 48 → 50. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

59% of holders stayed for 2+ years

■ 59% conviction (2yr+) ■ 21% medium ■ 20% new
134 out of 227 hedge funds have held PACB for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -7%, value -34%

Value
-33%
Shares
-6%
Last quarter: funds added -7% more shares while total portfolio value only changed -34%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🚀

Acceleration phase — new buyers rushing in

35 → 30 → 28 → 48 → 50 new funds/Q
New funds entering each quarter: 30 → 28 → 48 → 50. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 65% veterans vs 23% newcomers

■ 65% veterans ■ 12% 1-2yr ■ 23% new
Entry-cohort mix of 234 holders: 153 (65%) are 2+ year veterans, 28 entered 1–2 years ago, and 53 (23%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 27% AUM from major funds

27% from top-100 AUM funds
45 of 227 holders rank in the top 100 by AUM, accounting for 27% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.0
out of 10
Low Exit Risk
Exit risk score 3.0/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PACB

In 2026 Q1, 113 hedge funds were net buyers of PACB (50 opened a new position, 63 added to an existing one), while 110 reduced or exited (72 trimmed, 38 sold completely) — a 51% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 27% of total institutional value in PACB is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +12 funds (more new holders than closures). Total institutional holders: 227.

Hedge Fund Ownership: PACB

How many hedge funds hold PACB — quarterly history vs. share price
Quarterly hedge fund ownership of PACB vs. share price

Market Analysis: PACB

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PACB

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Pacific Biosciences Calif In (PACB) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PACB has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
PACB
+2.3%
XLV
+4.3%

PACB outperformed XLV by -2.0% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
PACB
+20.5%
XLV
+5.4%

Since the filing became public, PACB outperformed XLV by +15.1% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

24 top-rated funds 0 high-conviction
Consensus
6.1
/ 10
breadth
×
Elite
0.6
/ 10
conviction
Hedge Fund Positioning: PACB
226 + Investors

Track Smart Money conviction in PACB. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 226 215 5.12%
13F Shares 190M 204M -6.94%
Total Value $251M $379M -33.91%
New Positions 49 48 +1
Increased Positions 60 69 -9
Closed Positions 38 33 +5
Reduced Positions 71 47 +24
Total Calls 4 8 -50.0%
Total Puts 3 3 -
PUT/CALL Ratio 0.75 0.38 Neutral

Statistics: PACB

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

226 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PACB. Verified SEC 13F-HR filings.

QUARTER:
Top 25 PACB holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Pinegrove Venture Partners, LLC 1.31% 20,586 $27K
2 Birchview Capital, LP 1.13% 1,500,000 $2.0M
3 Bourne Lent Asset Management Inc 0.46% 951,055 $1.3M
4 ARK Investment Management LLC 0.37% 36,273,288 $47.9M
5 Green Alpha Advisors, LLC 0.24% 182,618 $241K
6 Softbank Group CORP. 0.24% 20,451,570 $27.0M
7 IQ EQ FUND MANAGEMENT (IRELAND) Ltd 0.18% 1,788,393 $2.4M
8 Amova Asset Management Americas, Inc. 0.13% 7,037,987 $9.2M
9 Koa Wealth Management, LLC 0.11% 120,000 $158K
10 Mirador Capital Partners LP 0.11% 604,884 $798K
11 Hhlr Advisors, LTD. 0.07% 918,892 $1.2M
12 Casdin Capital, LLC 0.07% 723,767 $955K
13 Carret Asset Management, LLC 0.07% 559,140 $738K
14 Scientech Research LLC 0.04% 38,450 $51K
15 Water Island Capital LLC 0.04% 272,040 $359K
16 Himension Capital (singapore) PTE. LTD. 0.03% 276,532 $365K
17 ArrowMark Colorado Holdings LLC 0.02% 468,382 $618K
18 Kavar Capital Partners Group, LLC 0.02% 93,319 $123K
19 NJ State Employees Deferred Compensation Plan 0.01% 100,000 $128K
20 Main Street Research LLC 0.01% 152,100 $201K
21 Caxton Associates LLP 0.01% 353,130 $466K
22 Sandbox Financial Partners, LLC 0.01% 27,517 $36K
23 Hartline Investment Corp/ 0.01% 69,000 $91K
24 AdvisorNet Financial, Inc 0.01% 142,057 $188K
25 DKM Wealth Management, Inc. 0.01% 10,000 $13K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Pacific Biosciences Calif In (PACB)

What does the Smart Money Trend signal show for PACB?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added PACB than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for PACB?

Slight buying edge — 51% buying: Last quarter: 113 funds bought or added vs 110 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for PACB holders?

Strong quality — 27% AUM from major funds: 45 of 227 holders rank in the top 100 by AUM, accounting for 27% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held PACB?

59% of holders stayed for 2+ years: 134 out of 227 hedge funds have held PACB for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Pacific Biosciences Calif In (PACB) following the 2026 Q1 hedge fund 13F filings?

As of today, PACB has moved +20.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +5.4% for the XLV sector ETF — an outperformance of +15.1%. Since the quarter end (March 31, 2026), PACB has gained +2.3% vs +4.3% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →